Should I buy or sell Syneos Health stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Syneos Health in the last year. There are currently 5 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" SYNH shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SYNH, but not buy additional shares or sell existing shares. View SYNH analyst ratings or view top-rated stocks .

What is Syneos Health's stock price target for 2024?

5 brokerages have issued 1 year price objectives for Syneos Health's stock. Their SYNH share price targets range from $28.00 to $51.00. On average, they predict the company's share price to reach $39.75 in the next twelve months. This suggests that the stock has a possible downside of 7.5%. View analysts price targets for SYNH or view top-rated stocks among Wall Street analysts .

How were Syneos Health's earnings last quarter?

Syneos Health, Inc. (NASDAQ:SYNH) issued its earnings results on Wednesday, November, 3rd. The company reported $1.22 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.17 by $0.05. The company had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.34 billion. Syneos Health had a trailing twelve-month return on equity of 8.63% and a net margin of 1.31%. The business's revenue was up 22.7% compared to the same quarter last year. During the same period last year, the business posted $0.93 earnings per share.

What ETFs hold Syneos Health's stock?

ETFs with the largest weight of Syneos Health (NASDAQ:SYNH) stock in their portfolio include First Trust Merger Arbitrage ETF (MARB) , AltShares Event-Driven ET (EVNT) , AltShares Merger Arbitrage ETF (ARB) , IQ Merger Arbitrage ETF (MNA) , ProShares Merger ETF (MRGR) , Invesco S&P MidCap 400 Pure Value ETF (RFV) , First Trust Health Care AlphaDEX Fund (FXH) and iShares Biotechnology ETF (IBB) .

What is Alistair Macdonald's approval rating as Syneos Health's CEO?

322 employees have rated Syneos Health Chief Executive Officer Alistair Macdonald on Glassdoor.com . Alistair Macdonald has an approval rating of 82% among the company's employees.

What other stocks do shareholders of Syneos Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Syneos Health investors own include NVIDIA (NVDA) , Pfizer (PFE) , Block (SQ) , Advanced Micro Devices (AMD) , Boeing (BA) , Alibaba Group (BABA) , ICON Public (ICLR) , Netflix (NFLX) , AbbVie (ABBV) and Intel (INTC) .

Who are Syneos Health's major shareholders?

Syneos Health's stock is owned by many different institutional and retail investors. Top institutional investors include Skandinaviska Enskilda Banken AB publ (0.13%), Natixis Advisors L.P. (0.01%), Barclays PLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Alistair Macdonald , Donna Hildebrand Kralowetz , International Corp/Ma Advent, Jason M Meggs , John L Maldonado , Jonathan Olefson , Linda S Harty , Mark E Jagiela, Matthew E Monaghan, Matthew E Monaghan , Michael Lee Brooks , Michelle Keefe , Thomas H Lee Advisors, Llc and Tom Allen. View institutional ownership trends .

Syneos Health Stock Price, News & Analysis (NASDAQ:SYNH)

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $42.97
▼
$42.99
50-Day Range: $42.48
▼
$42.98
52-Week Range: $22.89
▼
$52.23

Volume: 7.39 million shs
Average Volume: 1.92 million shs
Market Capitalization: $4.46 billion

P/E Ratio: 62.29
Dividend Yield: N/A
Price Target: $39.75

Stock Analysis Analyst Forecasts Earnings Headlines Insider Trades Ownership Short Interest Social Media Sustainability

Syneos Health MarketRank™ Stock Analysis

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 7.5% Downside
$39.75 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: -1.00
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.46 out of 5 stars

Medical Sector

892nd out of 957 stocks

Diagnostics & Research Industry

4th out of 4 stocks

1.0

Analyst's Opinion

Consensus Rating
Syneos Health has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 5 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $39.75, Syneos Health has a forecasted downside of 7.5% from its current price of $42.98.
Amount of Analyst Coverage
Syneos Health has received no research coverage in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for SYNH.

0.0

Dividend Strength

Dividend Yield
Syneos Health does not currently pay a dividend.
Dividend Growth
Syneos Health does not have a long track record of dividend growth.

4.5

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Syneos Health has received a 70.43% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Clinical research services for physical health", "Clinical research services for mental health", and "Management consulting for medical technology industry" products. See details.
Environmental Sustainability
The Environmental Impact score for Syneos Health is -1.00.

N/A

News and Social Media Coverage

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Syneos Health insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.34% of the stock of Syneos Health is held by insiders.
Percentage Held by Institutions
91.16% of the stock of Syneos Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Syneos Health is 62.29, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 115.43.
Price to Earnings Ratio vs. Sector
The P/E ratio of Syneos Health is 62.29, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 126.26.
Price to Book Value per Share Ratio
Syneos Health has a P/B Ratio of 1.27. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Syneos Health Stock (NASDAQ:SYNH)

Syneos Health, Inc., operates as an integrated biopharmaceutical solutions company. The company operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics in Phase I to IV of clinical development. This segment offers individual services, including regulatory consulting, project management, protocol development, investigational site recruitment, clinical monitoring, technology-enabled patient recruitment and engagement, clinical home health services, clinical trial diversity, biometrics, and regulatory affairs. The Commercial Solutions segment provides commercialization services, including deployment solutions, communications solutions, such as public relations, advertising, and medical communication; and consulting services. Its customers include companies in the biopharmaceutical, biotechnology, and medical device industries. It operates in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. The company has a strategic partnership with uMotif Limited to deliver patient-centric eClinical platform. The company was formerly known as INC Research Holdings, Inc. and changed its name to Syneos Health, Inc. in January 2018. Syneos Health, Inc. was incorporated in 2010 and is headquartered in Morrisville, North Carolina. As of September 28, 2023, Syneos Health, Inc. was taken private.

October 3, 2023 | tmcnet.com

Syneos Health Appoints Colin Shannon as Chief Executive Officer

October 3, 2023 | markets.businessinsider.com

Syneos Health Appoints Colin Shannon To Succeed Michelle Keefe As CEO

December 4, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.

October 2, 2023 | seekingalpha.com

SYNH Syneos Health, Inc.

September 28, 2023 | finance.yahoo.com

Syneos Health execs in line for huge payouts with $7B buyout

September 28, 2023 | finance.yahoo.com

Syneos Health Closes Transaction with Private Investment Firms

September 27, 2023 | finanznachrichten.de

S&P Dow Jones Indices: Civitas Resources Set to Join S&P MidCap 400; Hayward Holdings to Join S&P SmallCap 600

September 26, 2023 | finance.yahoo.com

Syneos Health Names Terttu Haring President, Clinical Sites & Patients

December 4, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

September 25, 2023 | stockhouse.com

Syneos Deadline Alert

September 23, 2023 | prnewswire.com

SYNEOS 72 HOUR DEADLINE ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Syneos To Contact Him Directly To Discuss Their Options

September 23, 2023 | businesswire.com

SYNEOS DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Syneos Health, Inc. and Encourages Investors to Contact ...

September 23, 2023 | businesswire.com

SYNEOS DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Syneos Health, Inc. and Encourages Investors to Contact the Firm

September 22, 2023 | benzinga.com

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Syneos Health, Inc. (SYNH)

September 18, 2023 | finance.yahoo.com

Here’s Why ClearBridge Investments Small Cap Strategy Sold Syneos Health (SYNH)

September 14, 2023 | stockhouse.com

FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in Syneos Health, Inc. with Losses of $100,000 to Contact the Firm

September 13, 2023 | businesswire.com

Final Deadline Approaching for Syneos Health, Inc. Investors: Kessler Topaz Meltzer & Check, LLP Reminds Syneos Health, Inc. (SYNH) Investors of September 25, 2023 Lead ...

September 13, 2023 | finance.yahoo.com

Syneos Health (SYNH) Declares Strategic Partnership With Oracle

September 12, 2023 | finanznachrichten.de

Syneos Health, Inc.: Syneos Health and Oracle to Expand Relationship to Accelerate Patient Recruitment & Advance Health Equity

September 11, 2023 | benzinga.com

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Syneos Health, Inc. (SYNH) Investors of a Class Action Lawsuit and Upcoming Deadline

September 10, 2023 | prnewswire.com

Syneos Health, Inc. (SYNH) Shareholder Reminder: Kessler Topaz Meltzer & Check, LLP Reminds SYNH Investors of Securities Fraud Class Action Lawsuit Filed On Their Behalf

September 8, 2023 | stockhouse.com

DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Syneos Health, Inc. with Losses of $100,000 to Contact the Firm

September 7, 2023 | finance.yahoo.com

Is It Too Late To Consider Buying Syneos Health, Inc. (NASDAQ:SYNH)?

September 7, 2023 | benzinga.com

SYNH Investors Should Contact Robbins LLP About Participating in the Class Action Against Syneos Health, Inc.

September 6, 2023 | finance.yahoo.com

Syneos Health, Inc. and Star Parent, Inc. Announce Proposed $1.70 Billion Offering of Senior Secured Notes

August 28, 2023 | prnewswire.com

SHAREHOLDER ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of September 25, 2023 in the Class Action Filed on Behalf of Syneos Health, Inc.(SYNH) Shareholders

August 27, 2023 | benzinga.com

TOP RANKED ROSEN LAW FIRM Encourages Syneos Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SYNH

See More Headlines

Receive SYNH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Syneos Health and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/03/2021
Today: 12/04/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Diagnostics & Research
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:SYNH
CUSIP: N/A
CIK: 1610950
Web: www.syneoshealth.com
Phone: (919) 876-9300
Fax: 919-876-9360
Employees: 28,768
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $39.75
High Stock Price Target: $51.00
Low Stock Price Target: $28.00
Potential Upside/Downside: -7.5%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): $0.69
Trailing P/E Ratio: 62.29
Forward P/E Ratio: 15.41
P/E Growth: N/A
Net Income: $266.50 million
Net Margins: 1.31%
Pretax Margin: 1.53%
Return on Equity: 8.63%
Return on Assets: 3.66%

Debt

Debt-to-Equity Ratio: 0.77
Current Ratio: 1.20
Quick Ratio: 1.20

Sales & Book Value

Annual Sales: $5.39 billion
Price / Sales: 0.83
Cash Flow: $6.72 per share
Price / Cash Flow: 6.40
Book Value: $33.96 per share
Price / Book: 1.27

Miscellaneous

Outstanding Shares: 103,720,000
Free Float: 103,366,000
Market Cap: $4.46 billion
Optionable: Optionable
Beta: 1.58

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Ms. Michelle Keefe (Age 56)
CEO & Director
Comp: $876.28k
Mr. Michael Lee Brooks (Age 49)
Chief Operating Officer
Comp: $702.11k
Mr. Jonathan Olefson Esq. (Age 47)
Gen. Counsel & Corp. Sec.
Comp: $526.13k
Mr. Christian Tucat MBA (Age 53)
Chief Bus. Officer
Comp: $517.29k
Mr. Jason M. Meggs (Age 47)
Consultant
Comp: $624.83k
Mr. Michael J. Bonello (Age 53)
Chief Financial Officer
Ms. Donna Hildebrand Kralowetz (Age 52)
Sr. VP of Fin. & Chief Accounting Officer
Mr. Baba Shetty
Pres of Technology & Data Solutions
Dr. Judith Ng-Cashin M.D. (Age 54)
Chief Scientific Officer
Mr. Larry A. Pickett Jr.
Chief Information & Digital Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

SYNH Stock Analysis - Frequently Asked Questions

Should I buy or sell Syneos Health stock right now?: 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Syneos Health in the last year. There are currently 5 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" SYNH shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SYNH, but not buy additional shares or sell existing shares.
View SYNH analyst ratings or view top-rated stocks.
What is Syneos Health's stock price target for 2024?: 5 brokerages have issued 1 year price objectives for Syneos Health's stock. Their SYNH share price targets range from $28.00 to $51.00. On average, they predict the company's share price to reach $39.75 in the next twelve months. This suggests that the stock has a possible downside of 7.5%.
View analysts price targets for SYNH or view top-rated stocks among Wall Street analysts.
How were Syneos Health's earnings last quarter?: Syneos Health, Inc. (NASDAQ:SYNH) issued its earnings results on Wednesday, November, 3rd. The company reported $1.22 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.17 by $0.05. The company had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.34 billion. Syneos Health had a trailing twelve-month return on equity of 8.63% and a net margin of 1.31%. The business's revenue was up 22.7% compared to the same quarter last year. During the same period last year, the business posted $0.93 earnings per share.
What ETFs hold Syneos Health's stock?: ETFs with the largest weight of Syneos Health (NASDAQ:SYNH) stock in their portfolio include First Trust Merger Arbitrage ETF (MARB), AltShares Event-Driven ET (EVNT), AltShares Merger Arbitrage ETF (ARB), IQ Merger Arbitrage ETF (MNA), ProShares Merger ETF (MRGR), Invesco S&P MidCap 400 Pure Value ETF (RFV), First Trust Health Care AlphaDEX Fund (FXH) and iShares Biotechnology ETF (IBB).

What is Alistair Macdonald's approval rating as Syneos Health's CEO?: 322 employees have rated Syneos Health Chief Executive Officer Alistair Macdonald on Glassdoor.com. Alistair Macdonald has an approval rating of 82% among the company's employees.
What other stocks do shareholders of Syneos Health own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Syneos Health investors own include NVIDIA (NVDA), Pfizer (PFE), Block (SQ), Advanced Micro Devices (AMD), Boeing (BA), Alibaba Group (BABA), ICON Public (ICLR), Netflix (NFLX), AbbVie (ABBV) and Intel (INTC).
Who are Syneos Health's major shareholders?: Syneos Health's stock is owned by many different institutional and retail investors. Top institutional investors include Skandinaviska Enskilda Banken AB publ (0.13%), Natixis Advisors L.P. (0.01%), Barclays PLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Alistair Macdonald, Donna Hildebrand Kralowetz, International Corp/Ma Advent, Jason M Meggs, John L Maldonado, Jonathan Olefson, Linda S Harty, Mark E Jagiela, Matthew E Monaghan, Matthew E Monaghan, Michael Lee Brooks, Michelle Keefe, Thomas H Lee Advisors, Llc and Tom Allen.
View institutional ownership trends.

This page (NASDAQ:SYNH) was last updated on 12/4/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Syneos Health Stock Price, News & Analysis (NASDAQ:SYNH)

Syneos Health MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

Company Ownership

Earnings and Valuation

About Syneos Health Stock (NASDAQ:SYNH)

SYNH Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

SYNH Stock Analysis - Frequently Asked Questions

Overall MarketRank^™